Abstract:Gonadotropin-releasing hormone (GnRH) antagonists have been shown to effectively prevent premature LH surge. This study aimed to evaluate the efficacy and safety of SHR7280, a novel small-molecule oral GnRH antagonist, in inhibiting premature LH surge in women undergoing COH in ART. This multicenter, open-label, dose-finding, phase 2 trial (NCT05082233) enrolled infertile women aged 20-39 years for whom in vitro fertilization or intracytoplasmic sperm injection was indicated. The starting dose of SHR7280 was 300 mg BID, followed by dose exploration in two lower dose groups (200 mg BID and 200 mg QD) sequentially. If an LH surge (LH >10 IU/L) occurred, the trial would be terminated in that dose group. SHR7280 was administrated orally on D5 of Gonal-F stimulation until hCG administration when ≥3 follicles with a diameter ≥17 mm or ≥2 follicles with ≥18 mm were observed. The primary endpoint was the rate of premature LH surge inhibition during SHR7280 treatment. A total of 85 patients received SHR7280 treatment (40 patients with 300 mg BID, 42 patients with 200 mg BID, and 3 patients with 200 mg QD) and the mean duration of exposure to SHR7280 was 5.7±1.2, 5.7±1.3, and 3.7±0.6 days (mean±SD), respectively. During SHR7280 treatment, 1 patient in the 200 mg QD group experienced a premature LH surge, yielding a rate of LH surge inhibition of 98.8% (84/85) in the study population. The mean number of oocytes retrieved in each patient was 10.3±4.9. The mean number of two pronuclei (2PN) oocytes that emerged 16-18h after fertilization was 6.3±3.0 and the mean number of embryos with grade I-II quality on D3 after fertilization was 3.9±2.4. Among the 71 patients who underwent fresh embryo transfer, 44 patients (62.0%, 95% CI 49.7-73.2) tested positive for serum β-hCG between D13-15 after embryo transfer and 38 (53.5%, 95% CI 41.3-65.5) were confirmed to be clinically pregnant. The mean total dose of Gonal-F was 1561.9±421.6 IU, with a mean duration of treatment lasting 8.8±1.4 days. The mean serum estradiol concentration on the day of hCG injection was 1620.1±940.5 pg/mL. No spontaneous ovulation occurred on the day of oocyte retrieval. Of the 85 patients, 37 (43.5%) experienced adverse events (AEs), the majority of which were mild in severity (29 [34.1%]). The most common AEs were premature labor (6 [7.1%]) and threatened abortion (5 [5.9%]). Two (2.4%) patients experienced treatment-related AEs. The drug exposure decreased with the decreasing dose and frequency of SHR7280 administration. The mean LH level on the day of hCG administration was 1.1±0.7, 2.0±1.6, 2.2±0.4 IU/L in the 300 mg BID, 200 mg BID, and 200 mg QD group, respectively. The use of SHR7280 in women undergoing COH for ART was associated with a high rate of early LH surge suppression, high quality embryos, and a high clinical pregnancy rate. The recommended minimum effective dose for early LH surge inhibition was 200 mg BID. SHR7280 was well-tolerated and safe.

Induction of Ovulation in Female Mud Skipper (boleophthalmus Pectinirest Ris) by HCG, Analogue of LHRH and Pimozide

Expression of Estrogen Receptor, Progesterone Receptor and Leukemia Inhibitory Factor on Endometrium During Different Ovarian Stimulation Protocols in Mice

The Activation of Residual Dormant Follicles by Human Chorionic Gonadotropin (HCG) in Vivo: a Novel Treatment for Premature Ovarian Insufficiency

P-676 Comparison of Hcg Triggering Versus Hcg in Combination with a GnRH Agonist: a Prospective Randomized Controlled Trial

Effects of luteinizing hormone-releasing hormone analog and pimozide on the release of luteinizing hormone and ovulation in artificially matured Japanese eel Anguilla japonica

A strategic approach to human resource planning in nursing.

Ovarian Stimulation Makes A Disruption of Imprinting Genes of Mouse Oocyte and Placenta.

Observations and temperatures of Io's Pele Patera from Cassini and Galileo spacecraft images

Transcriptome profiling reveals superovulation with the gonadotropin-releasing hormone agonist trigger impaired embryo implantation in mice

A progestin regulates the prostaglandin pathway in the neuroendocrine system in female mudskipper Boleophthalmus pectinirostris

[Effect of GnRHa controlled ovarian hyperstimulation on mouse embryo implantation and its mechanism]

Discussion of the Relative Factors about the Outcome of Ovulation and Pregnancy by Different Inducing Protocol and Fertilizing Style

Comparison of the Effect and Safety of GnRH-a or HCG in Ovulation Induction Cycles

Ovulation induction protocol using equine chorionic gonadotropin and porcine luteinizing hormone in the weaned sow

In view of ovarian steroidogenesis and luteal construction to explore the effects of Bushen Huoxue recipe in mice of ovarian hyperstimulation

Determination of gene point mutations by application of higher order central moments — Preliminary research

Adrenal cortical hormone levels in adrenal vein and peripheral blood.

Evaluation of Synthetic GnRH-Analog Peforelin with Regard to Oocyte Differentiation and Follicular Development in C57BL/6J Mice

Indocyanine green angiography in classic choroidal neovascularization.

ORAL GNRH ANTAGONIST SHR7280 FOR THE PREVENTION OF PREMATURE LUTEINIZING HORMONE (LH) SURGE IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION (COH) IN ASSISTED REPRODUCTIVE TECHNOLOGY (ART)

Effect of 200 μg of gonadorelin hydrochloride at the first GnRH of a CO-Synch program on ovulation rate and pregnancies per artificial insemination in Holstein heifers